Molecular Medicine

, Volume 21, Issue 1, pp 123–133 | Cite as

Opposite Prognostic Significance of Cellular and Serum Circulating MicroRNA-150 in Patients with Chronic Lymphocytic Leukemia

  • Basile Stamatopoulos
  • Michaël Van Damme
  • Emerence Crompot
  • Barbara Dessars
  • Hakim El Housni
  • Philippe Mineur
  • Nathalie Meuleman
  • Dominique Bron
  • Laurence Lagneaux
Research Article


MicroRNAs (or miRs) play a crucial role in chronic lymphocytic leukemia (CLL) physiopathology and prognosis. In addition, circulating microRNAs in body fluids have been proposed as new biomarkers. We investigated the expression of matched cellular and serum circulating microRNA-150 by quantitative real-time PCR (qPCR) from purified CD19+ cells or from CLL serums obtained at diagnosis in a cohort of 273/252 CLL patients with a median follow-up of 78 months (range 7–380) and correlated it to other biological or clinical parameters. We showed that miR-150 was significantly overexpressed in CLL cells/serums compared with healthy subjects (P < 0.0001). Among CLL patients, a low cellular miR-150 expression level was associated with tumor burden, disease aggressiveness and poor prognostic factors. In contrast, a high level of serum miR-150 was associated with tumor burden markers and some markers of poor prognosis. Similarly, cellular and serum miR-150 also predicted treatment-free survival (TFS) and overall survival (OS) in an opposite manner: patients with low cellular/serum miR-150 levels have median TFS of 40/111 months compared with high-level patients who have a median TFS of 122/60 months (P < 0.0001/P = 0.0066). Similar results were observed for OS. We also found that cellular and serum miR-150 levels vary in an opposite manner during disease progression and that cellular miR-150 could be regulated by its release into the extracellular space. Cellular and serum levels of miR-150 are associated with opposite clinical prognoses and could be used to molecularly monitor disease evolution as a new prognostic factor in CLL.



This work was financed by the Télévie fund (Fonds de la Recherche Scientifique — Fonds National de la Recherche Scientifique [F.R.S.-FNRS]).

Supplementary material

10020_2015_2101123_MOESM1_ESM.pdf (12.7 mb)
Supplementary material, approximately 12.7 MB.


  1. 1.
    Herishanu Y, Katz BZ, Lipsky A, Wiestner A. (2013) Biology of chronic lymphocytic leukemia in different microenvironments: clinical and therapeutic implications. Hematol. Oncol. Clin. North Am. 27:173–206.CrossRefGoogle Scholar
  2. 2.
    Hamblin T. (2002) Chronic lymphocytic leukaemia: one disease or two? Ann. Hematol. 81:299–303.CrossRefGoogle Scholar
  3. 3.
    Van Bockstaele F, Verhasselt B, Philippe J. (2009) Prognostic markers in chronic lymphocytic leukemia: a comprehensive review. Blood Rev. 23:25–47.CrossRefGoogle Scholar
  4. 4.
    Fabbri M, et al. (2008) MicroRNAs and noncoding RNAs in hematological malignancies: molecular, clinical and therapeutic implications. Leukemia. 22:1095–105.CrossRefGoogle Scholar
  5. 5.
    Bartel DP. (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 116:281–97.CrossRefGoogle Scholar
  6. 6.
    Chen CZ. (2005) MicroRNAs as oncogenes and tumor suppressors. N. Engl. J. Med. 353:1768–71.CrossRefGoogle Scholar
  7. 7.
    Weber JA, et al. (2010) The microRNA spectrum in 12 body fluids. Clin. Chem. 56:1733–41.CrossRefGoogle Scholar
  8. 8.
    Vickers KC, Remaley AT. (2012) Lipid-based carriers of microRNAs and intercellular communication. Curr. Opin. Lipidol. 23:91–7.CrossRefGoogle Scholar
  9. 9.
    Arroyo JD, et al. (2011) Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc. Natl. Acad. Sci. U. S. A. 108:5003–8.CrossRefGoogle Scholar
  10. 10.
    Rosell R, Wei J, Taron M. (2009) Circulating MicroRNA signatures of tumor-derived exosomes for early diagnosis of non-small-cell lung cancer. Clin. Lung Cancer. 10:8–9.CrossRefGoogle Scholar
  11. 11.
    Gilad S, et al. (2008) Serum microRNAs are promising novel biomarkers. PLoS One. 3:e3148.CrossRefGoogle Scholar
  12. 12.
    Pritchard CC, et al. (2012) Blood cell origin of circulating microRNAs: a cautionary note for cancer biomarker studies. Cancer Prev. Res. (Phila). 5:492–7.CrossRefGoogle Scholar
  13. 13.
    Mitchell PS, et al. (2008) Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl. Acad. Sci. U. S. A. 105:10513–8.CrossRefGoogle Scholar
  14. 14.
    Moussay E, et al. (2011) MicroRNA as biomarkers and regulators in B-cell chronic lymphocytic leukemia. Proc. Natl. Acad. Sci. U. S. A. 108:6573–8.CrossRefGoogle Scholar
  15. 15.
    He Y, Jiang X, Chen J. (2014) The role of miR-150 in normal and malignant hematopoiesis. Oncogene. 24;33:3887–93.CrossRefGoogle Scholar
  16. 16.
    Fulci V, et al. (2007) Quantitative technologies establish a novel microRNA profile of chronic lymphocytic leukemia. Blood. 109:4944–51.CrossRefGoogle Scholar
  17. 17.
    Mraz M, et al. (2014) MicroRNA-150 contributes to the proficiency of B-cell receptor signaling in chronic lymphocytic leukemia by regulating expression of GAB1 and FOXP1 genes. Blood. 124:84–95.CrossRefGoogle Scholar
  18. 18.
    Wang M, et al. (2008) miRNA analysis in B-cell chronic lymphocytic leukaemia: proliferation centres characterized by low miR-150 and high BIC/miR-155 expression. J. Pathol. 215:13–20.CrossRefGoogle Scholar
  19. 19.
    Papakonstantinou N, et al. (2013) Differential microRNA profiles and their functional implications in different immunogenetic subsets of chronic lymphocytic leukemia. Mol. Med. 19:115–23.CrossRefGoogle Scholar
  20. 20.
    Stamatopoulos B, et al. (2007) Quantification of ZAP70 mRNA in B cells by real-time PCR is a powerful prognostic factor in chronic lymphocytic leukemia. Clin. Chem. 53:1757–66.CrossRefGoogle Scholar
  21. 21.
    Stamatopoulos B, et al. (2009) microRNA-29c and microRNA-223 down-regulation has in vivo significance in chronic lymphocytic leukemia and improves disease risk stratification. Blood. 113:5237–45.CrossRefGoogle Scholar
  22. 22.
    McDonald JS, Milosevic D, Reddi HV, Grebe SK, Algeciras-Schimnich A. (2011) Analysis of circulating microRNA: preanalytical and analytical challenges. Clin. Chem. 57:833–40.CrossRefGoogle Scholar
  23. 23.
    Stamatopoulos B, et al. (2010) A molecular score by quantitative PCR as a new prognostic tool at diagnosis for chronic lymphocytic leukemia patients. PLoS One. 5:e12780.CrossRefGoogle Scholar
  24. 24.
    Ferrajoli A, et al. (2013) Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B-chronic lymphocytic leukemia. Blood. 122:1891–9.CrossRefGoogle Scholar
  25. 25.
    Budoni M, et al. (2013) The immunosuppressive effect of mesenchymal stromal cells on B lymphocytes is mediated by membrane vesicles. Cell Transplant. 22:369–79.CrossRefGoogle Scholar
  26. 26.
    Mahaweni NM, Kaijen-Lambers MEH, Dekkers J, Aerts JGJV, Hegmans JPJJ. (2013) Tumour-derived exosomes as antigen delivery carriers in dendritic cell-based immunotherapy for malignant mesothelioma. J. Extracell. Vesicles. 2:22492.CrossRefGoogle Scholar
  27. 27.
    Rassenti LZ, et al. (2008) Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia. Blood. 112:1923–30.CrossRefGoogle Scholar
  28. 28.
    Ito M, et al. (2014) MicroRNA-150 inhibits tumor invasion and metastasis by targeting the chemokine receptor CCR6 in advanced cutaneous T-cell lymphoma. Blood. 123:1499–511.CrossRefGoogle Scholar
  29. 29.
    Wang M, Yang W, Li M, Li Y. (2014) Low expression of miR-150 in pediatric intestinal Burkitt lymphoma. Exp. Mol. Pathol. 96:261–6.CrossRefGoogle Scholar
  30. 30.
    Yokobori T, et al. (2013) MiR-150 is associated with poor prognosis in esophageal squamous cell carcinoma via targeting the EMT inducer ZEB1. Cancer Sci. 104:48–54.CrossRefGoogle Scholar
  31. 31.
    Sun Y, et al. (2013) Expression of miR-150 and miR-3940-5p is reduced in non-small cell lung carcinoma and correlates with clinicopathological features. Oncol. Rep. 29:704–12.CrossRefGoogle Scholar
  32. 32.
    Ma Y, et al. (2012) miR-150 as a potential bio-marker associated with prognosis and therapeutic outcome in colorectal cancer. Gut. 61:1447–53.CrossRefGoogle Scholar
  33. 33.
    Mraz M, et al. (2009) miR-34a, miR-29c and miR-17-5p are downregulated in CLL patients with TP53 abnormalities. Leukemia. 23:1159–63.CrossRefGoogle Scholar

Copyright information

© The Author(s) 2015

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, and provide a link to the Creative Commons license. You do not have permission under this license to share adapted material derived from this article or parts of it.

The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.

To view a copy of this license, visit (

Authors and Affiliations

  • Basile Stamatopoulos
    • 1
  • Michaël Van Damme
    • 1
  • Emerence Crompot
    • 1
  • Barbara Dessars
    • 2
  • Hakim El Housni
    • 2
  • Philippe Mineur
    • 3
  • Nathalie Meuleman
    • 4
  • Dominique Bron
    • 4
  • Laurence Lagneaux
    • 1
  1. 1.Laboratory of Clinical Cell TherapyUniversité Libre de Bruxelles, Institut Jules BordetBruxellesBelgium
  2. 2.Department of Genetics, Erasme HospitalUniversité Libre de BruxellesBrusselsBelgium
  3. 3.Department of Hemato-OncologyGrand Hôpital de CharleroiGillyBelgium
  4. 4.Department of HematologyInstitut Jules BordetBrusselsBelgium

Personalised recommendations